FOLFOX-HAIC combined with lenvatinib and immune checkpoint inhibitors for hepatocellular carcinoma after the occurrence of TACE refractoriness:analysis of efficacy and safety
10.3969/j.issn.1008-794X.2024.06.005
- VernacularTitle:FOLFOX-HAIC联合仑伐替尼和免疫检查点抑制剂治疗TACE抵抗后肝细胞癌的疗效及安全性分析
- Author:
Lingfeng DIAO
1
;
Chendong WANG
;
Bin LENG
;
Ran YOU
;
Zeyu YU
;
Qingyu XU
;
Guowen YIN
Author Information
1. 221004 江苏徐州 徐州医科大学
- Keywords:
hepatocellular carcinoma;
TACE refractoriness;
hepatic arterial infusion chemotherapy;
lenvatinib;
immune checkpoint inhibitor
- From:
Journal of Interventional Radiology
2024;33(6):610-615
- CountryChina
- Language:Chinese
-
Abstract:
Objective To evaluate the efficacy and safety of fluorouracil and leucovorin and oxaliplatin(FOLFOX)regimen hepatic artery infusion chemotherapy(HAIC)combined with lenvatinib(LEN)and immune checkpoint inhibitors(ICIs)in treating patients with hepatocellular carcinoma(HCC)after the occurrence of transcatheter arterial chemoembolization(TACE)refractoriness.Methods The clinical data of 54 HCC patients who developed TACE refractoriness,were admitted to the Jiangsu Provincial Cancer Hospital of China to receive FOLFOX-HAIC combined with LEN and ICIs therapy between January 2019 and December 2022,were retrospectively analyzed.The modified Response Evaluation Criteria in Solid Tumors(mRECIST)was used to statistically analyze the clinical efficacy,the Common Terminology Criteria For Adverse Events version 5.0(CTCAE 5.0)was adopted to record and evaluate the treatment-related adverse events(TRAEs).The primary endpoints were progression-free survival(PFS)and overall survival(OS),the secondary endpoints were objective response rate(ORR),disease control rate(DCR),and safety.Results The median PFS was 11.7 months(95％CI:8.124-15.276 months),the median OS was 23.1 months(95％CI:19.508-26.692 months),the ORR was 46.3％,and the DCR was 87.0％.The most common TRAE at all levels was elevated alanine aminotransferase(51.9％),and the most common TRAE of grade 3/4 was hypertension(9.3％).No treatment-related death occurred.Conclusion For the treatment of HCC patients who developed TACE refractoriness,FOLFOX-HAIC combined LEN and ICIs is clinically safe and effective.(J Intervent Radiol,2024,33:610-615)
